Tibulizumab

DB14848InvestigationalProtein Based Therapies

Tibulizumab is under investigation in clinical trial NCT03736772 (A Study of LY3090106 in Japanese and Caucasian Healthy Participants).

Mechanism: Pharmacologically active on Tumor necrosis factor ligand superfamily member 13B and Interleukin-17A
Curator reviewed
Code names: LY3090106

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tibulizumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.